Experiences of Psychosocial Factors and Treatment Experiences Among Inpatients with Substance Use Disorders: A Questionnaire Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040930

Enrollment

150

Registered

2026-07-09

Start date

2026-07-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F10-F19

Interventions

Group 1: Patients who meet the inclusion criteria, do not meet any exclusion criteria, and wish to participate in the study will receive both verbal and written information about the study. Written in

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: o Provision of written informed consent to participate in the study o Age =18 years o Diagnosis of a substance use disorder o Undergoing inpatient detoxification treatment o Sufficient proficiency in German to understand and complete the questionnaires

Exclusion criteria

Exclusion criteria: Lack of capacity to provide informed consent

Design outcomes

Primary

Measure	Time frame
o Descriptive characterization of the assessed psychosocial factors (sleep, loneliness, conversations among fellow patients, symptom attribution, attitudes toward different patient groups, and shame) o Subjectively reported experiences and reasons associated with treatment discontinuation o Subjectively reported triggers, management strategies, and consequences of relapse during inpatient treatment o Prevalence of autistic traits in the study cohort Data will be collected once per participant using self-developed questionnaires: "Psychosocial Factors and Treatment Experiences in Inpatients with Substance Use Disorders: A Questionnaire Study" and, in the event of a relapse, the additional questionnaire section "Relapse During Inpatient Detoxification: Patients' Perspectives on Triggers, Management, and Consequences." In addition, the questionnaire incorporates the following standardized and validated instruments: o Autism-Spectrum Quotient (AQ) (Baron-Cohen et al., 2001) o Empathy Quotient (EQ) (Baron-Cohen et al., 2004) o Insomnia Severity Index (ISI) (Dieck et al., 2018) o Three-Item Loneliness Scale (Hughes et al., 2004) o 10-item Internalized Stigma of Mental Illness Scale (ISMI-10) (Boyd et al., 2014)	—

Measure

Time frame

o Descriptive characterization of the assessed psychosocial factors (sleep, loneliness, conversations among fellow patients, symptom attribution, attitudes toward different patient groups, and shame) o Subjectively reported experiences and reasons associated with treatment discontinuation o Subjectively reported triggers, management strategies, and consequences of relapse during inpatient treatment o Prevalence of autistic traits in the study cohort Data will be collected once per participant using self-developed questionnaires: "Psychosocial Factors and Treatment Experiences in Inpatients with Substance Use Disorders: A Questionnaire Study" and, in the event of a relapse, the additional questionnaire section "Relapse During Inpatient Detoxification: Patients' Perspectives on Triggers, Management, and Consequences." In addition, the questionnaire incorporates the following standardized and validated instruments: o Autism-Spectrum Quotient (AQ) (Baron-Cohen et al., 2001) o Empathy Quotient (EQ) (Baron-Cohen et al., 2004) o Insomnia Severity Index (ISI) (Dieck et al., 2018) o Three-Item Loneliness Scale (Hughes et al., 2004) o 10-item Internalized Stigma of Mental Illness Scale (ISMI-10) (Boyd et al., 2014)

—

Secondary

Measure	Time frame
o Investigation of the associations between psychosocial factors and clinical as well as sociodemographic characteristics (e.g., type of substance use, duration of substance dependence, and previous treatment) o Investigation of the association between autistic traits and substance use	—

Countries

Germany

Contacts

Public ContactMandy Roy

Asklepios Klinik Ochsenzoll, Klinik für Abhängigkeitserkrankungen

m.roy@asklepios.com+49 40 1818872524

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026